GLI1 and plasma cell myeloma: HDAC inhibitors are approved for the treatment of T cell lymphomas and multiple myeloma, suggesting that these agents could inhibit GLI activity in the clinical setting either alone or in combination with other GLI targeting agents, such as aPKC inhibitors [78,79].